Navigation Links
Researchers find a treatment for deadly brain tumor

Providence, RI New research at Rhode Island Hospital has identified a treatment in animal models for glioblastomas deadly brain tumors which, once diagnosed, offer a poor prognosis and relatively short life expectancy. Using a synthetic form of a naturally-occurring hormone combined with chemotherapy, researchers were able to inhibit tumor growth and achieve a 25 percent cure rate. The study and their findings are published in the Journal of Oncology.

Led by Suzanne de la Monte, MD, MPH, of Rhode Island Hospital, researchers studied the effects of Thymosin Alpha 1 (Talpha1/thymalfasin), a synthetic form of the naturally occurring hormone Thymosin produced by the thymus gland. De la Monte, who is also a professor of neuroscience at The Warren Alpert Medical School of Brown University, says, "Our hypothesis was that the immune system basically needs a boost to kill the cancer cells. We know that Thymosin is currently being used in Europe to treat cancer, so we set out to see what effect this could have on glioblastomas."

What the investigators found is that when Talpha1 was used alone, the tumor continued to eventually grow. When they combined the Talpha1 with a common chemotherapeutic agent, there was a dramatic effect. De la Monte explains, "We looked at giving chemo plus Talpha1 as a sort of immune booster. What we found is that when you give Talpha1 and the chemo agent together, not only do you have a slower rate of tumor growth with cells being killed, but there have also been cures. We achieved a 25 percent cure rate in these animal models."

Co-investigator Jack Wands, MD, also a physician with University Medicine Foundation and a professor Alpert Medical School, says, "In this study we used a natural hormone that's been produced in the thymus gland, which by itself has no anti-tumor effect and in fact can be harmful in high doses. What's important in this study is that we have found with low to moderate doses in combination with a well-known chemotherapeutic agent, it has a striking ability to inhibit the growth of a glioblastoma in animal models."

The researchers went on to further investigate how the Talpha1 was achieving this response. What they discovered is that it sensitizes the tumor cells to the chemotherapeutic agent, giving the agent more of an impact upon the tumor than it would have on its own. De la Monte explains, "The thymic hormone is actually working to boost immune response and basically activates a killing of the tumor cells."

De la Monte says the next step is to bring this to a Phase I clinical trial. "You're talking about a disease where people are dead within months. There is no cure." Wands agrees and says, "Our pre-clinical studies have shown this striking effect and we believe the next step is to try this approach in patients with this devastating illness."


Contact: Nancy Cawley Jean

Related medicine news :

1. Researchers find new insights into inherited retinal disease
2. Pitt researchers raise concern over frequency of surveillance colonoscopy
3. Stress triggers tumor formation, Yale researchers find
4. Johns Hopkins researchers say vaccine appears to mop up leukemia cells Gleevec leaves behind
5. St. Johns wort not helpful treatment for irritable bowel syndrome, Mayo Clinic researchers say
6. Young hunters most likely to be injured using tree stands, say UAB researchers
7. Researchers find clues to why some continue to eat when full
8. Researchers find new patterns in H1N1 deaths
9. Researchers discover gene therapy to prevent progression of emphysema
10. Researchers at the John Theurer Cancer Center Present Cutting-Edge Research Results at this Years American Society of Hematology Annual Meeting
11. Vision researchers Jay and Maureen Neitz to receive first Pepose Award from Brandeis
Post Your Comments:
(Date:12/1/2015)... ... 2015 , ... The North American Meat Institute today unveiled ... poultry play in a healthy, balanced diet. , includes a section about ... their “meat IQ,” a section offering straight talk on controversies, information on buying ...
(Date:12/1/2015)... , ... December 01, 2015 , ... Royal River Natural ... new study that found post-menopausal women who took the nutritional supplement creatine, along with ... who trained but did not take creatine. , The report is part of the ...
(Date:12/1/2015)... , ... December 01, 2015 , ... ... oncology and hematology continuing medical education (CME), today announced that the first annual ... Hyatt New York. , “The prevention, detection and treatment of gastrointestinal cancers are ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... professionals who believe that with innovative technologies and under the right circumstances, these ... get the benefit of a dual-approach to his or her therapeutic sessions, as ...
(Date:12/1/2015)... ... December 01, 2015 , ... CloudLIMS today announced that ... Business Awards under the New Products and Services category for its innovative product ... management software that helps labs organize data and track samples with storage ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... , Dec. 01, 2015 ... of the "Veterinary Equipment and Disposables Market ... 2020" report to their offering. --> ... the "Veterinary Equipment and Disposables Market by ... report to their offering. --> ...
(Date:12/1/2015)... New York , December 1, 2015 ... Contraceptive Pills, Contraceptive Injectables, Topical Contraceptives, Male ... Implants, Contraceptive Vaginal Rings, Contraceptive Diaphragms, Contraceptive ... Industry Analysis, Size, Share, Growth, Trends and ... released by Transparency Market Research (TMR).The report ...
(Date:12/1/2015)... SAN DIEGO , Dec. 1, 2015   ... oncology drug development company, announces it has filed an ... and Drug Administration (FDA) for the Company,s lead fully ... Subject to FDA acceptance, MabVax plans to initiate the ... --> --> The planned ...
Breaking Medicine Technology: